NASDAQ:ATXI
Avenue Therapeutics, Inc. Stock News
$3.73
+0.100 (+2.75%)
At Close: May 17, 2024
Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024 Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
08:30am, Wednesday, 15'th May 2024
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Ave
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
08:00am, Monday, 29'th Apr 2024
MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercializat
Avenue Therapeutics Announces Reverse Stock Split
07:30am, Wednesday, 24'th Apr 2024
MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercializat
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
08:30am, Monday, 25'th Mar 2024
MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercializat
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
04:05pm, Monday, 18'th Mar 2024
- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 -
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
08:15am, Friday, 15'th Mar 2024
MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercializat
BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of r
-In vivo data supports BAER-101's unique ability to significantly suppress seizures using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy- -In vivo
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
08:00am, Thursday, 11'th Jan 2024
MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercializati
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
09:15am, Friday, 05'th Jan 2024
MIAMI, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercializati
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
08:30am, Thursday, 04'th Jan 2024
MIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercializati
- Topline data remains on track for second quarter of 2024 - MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmace
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
08:30am, Friday, 01'st Dec 2023
MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercializati
Why Is Avenue Therapeutics (ATXI) Stock Up 59% Today?
08:05am, Wednesday, 29'th Nov 2023
Avenue Therapeutics (NASDAQ: ATXI ) stock is rising higher after the company revealed a major investment from Robert Davidow. According to a filing with the Securities and Exchange Commission (SEC),
